New MOU pairs GlycanAge’s glycan-based biological age test with ExoEarth’s exosome platform, bringing inflammaging testing deeper into Japan.
Biological age testing is having a moment, and it has just gained a foothold in one of the world’s most aging-literate markets. GlycanAge, the UK-based company behind a glycan test that measures inflammaging, has signed a memorandum of understanding with ExoEarth Corporation, a Tokyo life sciences firm, to expand biological age testing across Japan and run joint research into the biology of aging.
The deal is really two deals folded into one: a commercial push to get GlycanAge testing in front of more people in Japan, and a scientific collaboration that tries to connect two fairly different corners of longevity research.
GlycanAge built its business on glycans, sugar molecules attached to proteins in the blood, as a way of reading immune-system inflammation before it shows up on a standard blood panel. The company says its work draws on more than 30 years of glycoscience research and over 350 peer-reviewed publications.
ExoEarth’s angle is different. The company has focused its efforts on EXOCURE, a platform built around extracellular vesicles, tiny particles that cells use to communicate, sourced from stem cells derived from human exfoliated deciduous dental pulp – essentially, cells recovered from baby teeth. It’s an unusual starting material, but one that’s carved out a niche in Japan’s regenerative medicine scene.
Put the two together, and the pitch is that immune-aging biomarkers (GlycanAge’s specialty) and exosome biology (ExoEarth’s) can be tracked against each other over time, rather than studied in isolation.
The partnership calls for a longitudinal joint research program that uses GlycanAge testing to track biological-age and immune-related changes over time in people going through ExoEarth’s EXOCURE program. That’s about as specific as the announcement gets for now. The companies say details on participant numbers, how often measurements will be taken, and the exact research protocols are still being worked out, pending scientific, medical, ethical and regulatory review. In other words, the framework is signed, the study design isn’t finished yet.
“Japan is one of the world’s most advanced longevity markets, and ExoEarth is an ideal partner both to bring GlycanAge to more people here and to explore new science together. Combining our glycan biomarkers with ExoEarth’s expertise in exosome biology opens up exciting avenues for understanding how we age,” said Nikolina Lauc, CEO of GlycanAge.
ExoEarth’s chief executive, Takashi Nishihira, framed the collaboration in more personal terms.
“From my own experience of continuously tracking my GlycanAge since my sixties, I have come to believe that age is more than just a number – it can serve as an important indicator for understanding and managing our own health. Through this collaboration with GlycanAge, we aim to promote a new culture of healthy longevity built around a simple cycle: measure, understand, act, and measure again. Together, we hope to bring this approach to the world,” he said.
Japan isn’t a random choice of market. It has one of the oldest populations on the planet, a well-established culture of preventive health checkups and consumers who are, by most accounts, comfortable paying for detailed health data about themselves. For a company selling a biological age test, that’s about as favorable a backdrop as exists anywhere.
It also fits a pattern that’s become familiar in the longevity space over the past couple of years: Western biomarker companies partnering with Asian life sciences firms rather than trying to build local distribution from scratch. The regulatory and cultural terrain in Japan’s healthcare system rewards local partnership over a solo entry.
What this deal really represents is an attempt to answer a question the longevity field keeps circling back to: does knowing your biological age actually change anything? GlycanAge and ExoEarth are betting that pairing two different biomarker systems, and tracking them over time rather than as one-off snapshots, gets closer to an answer than either test could on its own.
The research protocol isn’t public yet, but the underlying wager is the same one the entire biological-age testing industry is making: that measurement, done often enough and combined with the right intervention, becomes something people can actually act on, rather than a statistic that just tells them how worried to be.
